Short selling resumed on the 3rd, and Celltrion, the target of which was selected as the target, announced it as a “diagnostic kit permission” before the opening, and immediately after the stock market closed, it was announced again as “adding a brand”, leading to controversy over the stock price manipulation to defend against the short selling offensive.
Celltrion announced in a press release on the 3rd that it was “acquired conditional permission for the corona self-test kit from the Ministry of Food and Drug Safety” at 9 am on the 3rd.
Celltrion's press release, released before the stock market opened, said that the Corona self-test kit'diatrust home test' obtained conditional approval from the Ministry of Food and Drug Safety on the 30th of last month. “We will quickly supply self-test kits through a distribution network including Celltrion Pharmaceutical, which is responsible for domestic distribution of our products.”
After the stock market closes, “Celltrion has not obtained a separate license for the product (diatrust) as of April 30.” “The model name'Diartrust Home Test' has been added to the existing Humasis license and can be sold in Korea. It has become.”
The press release on this day when the short sale took place is ‘conditional permission on April 30 from the Ministry of Food and Drug Safety, and the press release for stock price rise usually takes two days, unlike the practice announced immediately after the next day, and organizational intervention is predicted.
Celltrion, which was designated as a corona treatment partner by the government in February of last year and received intensive support of more than 50 billion won, has more than quadrupled its stocks at the end of last year from the beginning of the coronavirus1, reaching 396,200 won on February 7th. In contrast to the development conditions, the mild treatment was changed to severe, and the'conditional approval' for phase 3 clinical trial was issued, falling and falling, and on May 3, it fell 37% to 245,500.
The stock price of Celltrion led to a rise in stock prices as the quarantine authorities disclosed information to related companies at a briefing, and became a target for short selling, down 6.2% from the previous trading day on the 3rd of the partial resumption.
Humasis is the largest beneficiary of the government's self-diagnosis kit, with the fourth trend in April, and the share price soared 74.98% for one month.
In the press release, Chosun Biz reported that Celltrion said, “It was corrected to correct the incorrect information,” and “I know that the addition of a domestic brand is an accurate expression.”
The Ministry of Food and Drug Safety (KFDA) revised the'Regulations on In Vitro Diagnosis Medical Device Permit, Report, Review, etc.' saying that it was support for export customs clearance of diagnostic kits in December last year as the cause of k quarantine. The measure seems to have given preferential measures to Celltrion for domestic sales products, not exports.
It is an administrative measure that the Ministry of Food and Drug Safety gives Celltrion a separate “permission” for the “diatrust home test” that Celltrion announced at 5 o'clock on the same day.
On the 3rd, the short selling of the stock market was KOSPI 814 billion won, KOSDAQ 279 billion 2904 million won, of a total of 1.93 trillion 7204 million won, of which foreigners accounted for 90% by short selling 9558 billion won, and Celltrion, the No. 1 celltrion, accounted for 70% of the total transaction amount. It accounted for 14.77%.
Shortly before the resumption of short selling, Korean securities firms are rushing to report'limited and bull market valid', saying, “The impact of the market unit caused by the resumption of short selling is not enough to be of concern” (Samsung Securities), “Resumption of short selling is unlikely to be a factor in the stock price decline” (Shinhan Geumtu), “Even when short selling is resumed, the trend of improving profits has not been impaired considering domestic export performance, so the bull market is valid” (Kiwoom Securities).
Yonhap News reported on the 5th <"Celltrion corona treatment and severe aggravation significantly decreased" subtitle-Rekkirona, Busan Medical Center that prescribed 450 people... In the article "Reduction of the period of stay">
The number of patients who were prescribed remdesivir from the head of the intensive care unit of the Busan Medical Center was 143 from December 1 to February 17 last year, but from February 19 to April 17, after the prescription of Rekirona began, 28 patients. In the article, the title of "Degree"> and other imported drugs and celltrion treatment results were announced in the article.
Prior to the resumption of short selling, the Financial Services Commission introduced a punishment system for illegal short selling for up to 30 terms for more than one year and a penalty penalty of 3-5 times unfair gains.